$DRIO
DarioHealth Corp. Stock $drio

$drio Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-Q Financial Statement

#000114420416133274 Filed on November 10, 2016

Income Statement

Concept	2016 Q4	2016 Q3	2015 Q3
Revenue	$840.0K	$728.0K	$273.0K
YoY Change	170.97%	166.67%
Cost Of Revenue	$1.220M	$652.0K	$404.0K
YoY Change	114.04%	61.39%	-30.94%
Gross Profit	-$380.0K	$76.00K	-$131.0K
YoY Change	46.15%	-158.02%	-77.61%
Gross Profit Margin	-45.24%	10.44%	-47.99%
Selling, General & Admin	$2.610M	$2.140M	$1.750M
YoY Change	153.4%	22.29%	52.17%
% of Gross Profit		2815.79%
Research & Development	$580.0K	$659.0K	$667.0K
YoY Change	1.75%	-1.2%	-13.26%
% of Gross Profit		867.11%
Depreciation & Amortization	$120.0K	$80.00K	$90.00K
YoY Change	33.33%	-11.11%	-10.0%
% of Gross Profit		105.26%
Operating Expenses	$3.180M	$2.797M	$2.416M
YoY Change	98.75%	15.77%	25.7%
Operating Profit	-$3.560M	-$2.721M	-$2.547M
YoY Change	91.4%	6.83%	1.6%
Interest Expense	-$1.430M	$2.110M	$730.0K
YoY Change	-815.0%	189.04%	-71.92%
% of Operating Profit
Other Income/Expense, Net	$20.00K	$2.110M	$718.0K
YoY Change	-300.0%	193.87%	-225.96%
Pretax Income	-$5.240M	-$610.0K	-$1.830M
YoY Change	213.77%	-66.67%	-40.58%
Income Tax
% Of Pretax Income
Net Earnings	-$5.240M	-$611.0K	-$1.829M
YoY Change	213.77%	-66.59%	-40.56%
Net Earnings / Revenue	-623.81%	-83.93%	-669.96%
Basic Earnings Per Share			-$0.05
Diluted Earnings Per Share	-$18.07M	-$2.103M	-$0.05
COMMON SHARES
Basic Shares Outstanding	5.713M shares	5.713M shares	37.43M shares
Diluted Shares Outstanding			37.43M shares

Balance Sheet

Concept	2016 Q4	2016 Q3	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.300M	$3.600M	$2.000M
YoY Change	-53.57%	80.0%	-53.49%
Cash & Equivalents	$1.093M	$3.339M	$1.908M
Short-Term Investments	$200.0K	$200.0K	$100.0K
Other Short-Term Assets	$64.00K		$0.00
YoY Change	190.91%
Inventory	$888.0K	$1.100M	$315.0K
Prepaid Expenses
Receivables	$0.00	$300.0K
Other Receivables	$500.0K	$600.0K
Total Short-Term Assets	$2.936M	$5.600M	$2.721M
YoY Change	-31.51%	105.81%	-42.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$901.0K	$1.100M	$796.0K
YoY Change	20.29%	38.19%	-35.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00	$0.00
YoY Change
Total Long-Term Assets	$936.0K	$1.100M	$829.0K
YoY Change	18.48%	32.69%	-34.93%
TOTAL ASSETS
Total Short-Term Assets	$2.936M	$5.600M	$2.721M
Total Long-Term Assets	$936.0K	$1.100M	$829.0K
Total Assets	$3.872M	$6.700M	$3.550M
YoY Change	-23.73%	88.73%	-40.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.800M	$1.000M	$900.0K
YoY Change	80.0%	11.11%	-30.77%
Accrued Expenses	$622.0K
YoY Change	43.32%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.925M	$2.000M	$1.500M
YoY Change	73.08%	33.33%	-28.37%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$2.400M
YoY Change	-100.0%	-100.0%	-58.62%
Other Long-Term Liabilities	$7.500M	$300.0K	$3.600M
YoY Change	188.46%	-91.67%	16.13%
Total Long-Term Liabilities	$7.500M	$300.0K	$6.000M
YoY Change	50.0%	-95.0%	-32.58%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.925M	$2.000M	$1.500M
Total Long-Term Liabilities	$7.500M	$300.0K	$6.000M
Total Liabilities	$10.40M	$2.300M	$7.500M
YoY Change	55.22%	-69.33%	-31.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$54.96M		-$41.68M
YoY Change	26.77%		27.96%
Common Stock	$6.000K		$4.000K
YoY Change	20.0%		100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$6.541M	$4.400M	-$3.960M
YoY Change
Total Liabilities & Shareholders Equity	$3.872M	$6.700M	$3.550M
YoY Change	-23.73%	88.73%	-40.85%

Cashflow Statement

Concept	2016 Q4	2016 Q3	2015 Q3
OPERATING ACTIVITIES
Net Income	-$5.240M	-$611.0K	-$1.829M
YoY Change	213.77%	-66.59%	-40.56%
Depreciation, Depletion And Amortization	$120.0K	$80.00K	$90.00K
YoY Change	33.33%	-11.11%	-10.0%
Cash From Operating Activities	-$1.860M	-$2.720M	-$1.380M
YoY Change	-10.14%	97.1%	-21.14%
INVESTING ACTIVITIES
Capital Expenditures	-$400.0K	-$160.0K	-$20.00K
YoY Change	900.0%	700.0%	-71.43%
Acquisitions
YoY Change
Other Investing Activities	$10.00K	-$150.0K	$10.00K
YoY Change	-200.0%	-1600.0%	-85.71%
Cash From Investing Activities	-$390.0K	-$310.0K	-$20.00K
YoY Change	875.0%	1450.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	2.320M
YoY Change	-100.0%	-100.0%	-43.41%
NET CHANGE
Cash From Operating Activities	-1.860M	-2.720M	-1.380M
Cash From Investing Activities	-390.0K	-310.0K	-20.00K
Cash From Financing Activities	0.000	0.000	2.320M
Net Change In Cash	-2.250M	-3.030M	920.0K
YoY Change	-392.21%	-429.35%	-60.85%
FREE CASH FLOW
Cash From Operating Activities	-$1.860M	-$2.720M	-$1.380M
Capital Expenditures	-$400.0K	-$160.0K	-$20.00K
Free Cash Flow	-$1.460M	-$2.560M	-$1.360M
YoY Change	-28.08%	88.24%	-19.05%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.13
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5019918	shares
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2006000	USD
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.31
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5705229	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.42
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1657550	shares
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	455000	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	USD
CY2016Q3	us-gaap	Revenues Revenues	728000	USD
CY2015Q3	us-gaap	Revenues Revenues	273000	USD
CY2016Q3	us-gaap	Cost Of Revenue CostOfRevenue	652000	USD
CY2015Q3	us-gaap	Cost Of Revenue CostOfRevenue	404000	USD
CY2016Q3	us-gaap	Gross Profit GrossProfit	76000	USD
CY2015Q3	us-gaap	Gross Profit GrossProfit	-131000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	659000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	667000	USD
CY2016Q3	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	1533000	USD
CY2015Q3	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	417000	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	605000	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1332000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	2797000	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	2416000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2721000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2547000	USD
CY2016Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1658000	USD
CY2015Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-753000	USD
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	980000	USD
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	718000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-1741000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-1829000	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1829000	USD
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.90
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2079622	shares
CY2016Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	USD
CY2015Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	USD
CY2016Q3	drio	Deemed Dividend Related To Warrants Exchange Agreement DeemedDividendRelatedToWarrantsExchangeAgreement	0	USD
CY2015Q3	drio	Deemed Dividend Related To Warrants Exchange Agreement DeemedDividendRelatedToWarrantsExchangeAgreement	0	USD
	drio	Deemed Dividend Related To Warrants Exchange Agreement DeemedDividendRelatedToWarrantsExchangeAgreement	0	USD
	drio	Deemed Dividend Related To Warrants Exchange Agreement DeemedDividendRelatedToWarrantsExchangeAgreement	154000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-5295000	USD
CY2015	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	998000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	481000	USD
CY2015	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	400000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	2277000	USD
CY2015	drio	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	60000	USD
CY2015	drio	Receipts On Account Of Shares ReceiptsOnAccountOfShares	20000	USD
CY2015	drio	Warrants Issued During Period Value In November And December2015 WarrantsIssuedDuringPeriodValueInNovemberAndDecember2015	822000	USD
CY2015	drio	Deemed Dividend Inducement Of Warrant Exercise In May2015 DeemedDividendInducementOfWarrantExerciseInMay2015	0	USD
	drio	Payment For Executives And Directors Under Salary Program PaymentForExecutivesAndDirectorsUnderSalaryProgram	154000	USD
	drio	Payment For Executives And Directors Under Salary Program PaymentForExecutivesAndDirectorsUnderSalaryProgram	192000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	283000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-58000	USD
	us-gaap	Payments For Proceeds From Other Loans And Leases PaymentsForProceedsFromOtherLoansAndLeases	-1000	USD
	drio	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	210000	USD
CY2015	drio	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	453000	USD
CY2015	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	304000	USD
CY2016Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	628000	USD
CY2015Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	132000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	310000	USD
CY2015	drio	Issuance Of Common Stock In September2015 To Employees Compensation IssuanceOfCommonStockInSeptember2015ToEmployeesCompensation	591000	USD
CY2015	drio	Issuanceof Common Stock In April August And December2015 To Service Provider IssuanceofCommonStockInAprilAugustAndDecember2015ToServiceProvider	118000	USD
CY2015	drio	Stock Issued During Period Value New Issues December2015 StockIssuedDuringPeriodValueNewIssuesDecember2015	500000	USD
CY2015	drio	Stock Issued During Period Value New Issues November2015 StockIssuedDuringPeriodValueNewIssuesNovember2015	2294000	USD
CY2015	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2325000	USD
CY2015	drio	Stock Issued During Period Value New Issues February2015 StockIssuedDuringPeriodValueNewIssuesFebruary2015	1956000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5038000	USD
CY2015	drio	Issuance Of Common Stock In September2015 To Service Provider IssuanceOfCommonStockInSeptember2015ToServiceProvider	16000	USD
	drio	Stock Issued During Period Private Placement Value New Issues March2016 StockIssuedDuringPeriodPrivatePlacementValueNewIssuesMarch2016	2500000	USD
	drio	Deemed Dividend Related To Change In Conversion Term Of Series Preferred Stock Value DeemedDividendRelatedToChangeInConversionTermOfSeriesPreferredStockValue	0	USD
	drio	Stock Issued During Period Value Issued To Officer StockIssuedDuringPeriodValueIssuedToOfficer	86000	USD
	drio	Issuance Of Common Stock In January2016 To Service Provider IssuanceOfCommonStockInJanuary2016ToServiceProvider	37000	USD
	us-gaap	Depreciation Depreciation	248000	USD
	us-gaap	Depreciation Depreciation	273000	USD
	drio	Increase Decrease In Accounts Receivables And Prepaid Expense IncreaseDecreaseInAccountsReceivablesAndPrepaidExpense	120000	USD
	drio	Increase Decrease In Accounts Receivables And Prepaid Expense IncreaseDecreaseInAccountsReceivablesAndPrepaidExpense	-80000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	183000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	49000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4214000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6520000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	517000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	81000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-560000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-65000	USD
	drio	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	7538000	USD
	drio	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	1956000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	7748000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	4734000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	668000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	455000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1453000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1908000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	26000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	400000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	406000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	70000	USD
	us-gaap	Payments For Proceeds From Other Loans And Leases PaymentsForProceedsFromOtherLoansAndLeases	-12000	USD
	drio	Proceeds From Stock Options And Warrants Exercised ProceedsFromStockOptionsAndWarrantsExercised	210000	USD
	drio	Increase Decrease In Fair Value Of Warrants IncreaseDecreaseInFairValueOfWarrants	2315000	USD
	drio	Increase Decrease In Fair Value Of Warrants IncreaseDecreaseInFairValueOfWarrants	377000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-31000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	30000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	8000	USD
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	USD
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	453000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	155000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	330000	USD
CY2016Q3	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	490000	USD
CY2015Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	469000	USD
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2911788	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2911788	shares
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q3	drio	Deemed Dividend Related To Exchange Agreement DeemedDividendRelatedToExchangeAgreement	265000	USD
CY2015Q3	drio	Deemed Dividend Related To Exchange Agreement DeemedDividendRelatedToExchangeAgreement	0	USD
	drio	Deemed Dividend Related To Exchange Agreement DeemedDividendRelatedToExchangeAgreement	265000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	195000	USD
CY2015	us-gaap	Inventory Write Down InventoryWriteDown	193000	USD
CY2016Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	778000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y1M20D
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	481000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	768000	USD
	drio	Bank Charges BankCharges	17000	USD
	drio	Bank Charges BankCharges	41000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	6000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-6000	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	DarioHealth Corp.
	dei	Entity Central Index Key EntityCentralIndexKey	0001533998
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	DRIO
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5713383	shares
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	160000000	shares
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	160000000	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5713383	shares
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5713383	shares
	drio	Deemed Dividend Related To Exchange Agreement DeemedDividendRelatedToExchangeAgreement	0	USD
	drio	Deemed Dividend Inducement Of Warrant Exercise In May2015 DeemedDividendInducementOfWarrantExerciseInMay2015	0	USD
CY2015	drio	Issuance Of Common Stock And Warrants In February2015 IssuanceOfCommonStockAndWarrantsInFebruary2015	3.24
CY2015	drio	Issuance Of Common Stock In July And August2015 IssuanceOfCommonStockInJulyAndAugust2015	5.40
CY2015	drio	Issuance Of Common Stock November2015 IssuanceOfCommonStockNovember2015	5.40
CY2015	drio	Issuance Of Common Stock December2015 IssuanceOfCommonStockDecember2015	6.16
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		USD
	us-gaap	Payments For Proceeds From Loans Receivable PaymentsForProceedsFromLoansReceivable	0	USD
	us-gaap	Payments For Proceeds From Loans Receivable PaymentsForProceedsFromLoansReceivable	-333000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	10000	USD
	drio	Proceeds From Issuance Of Common Stock And Warrants1 ProceedsFromIssuanceOfCommonStockAndWarrants1	2325000	USD
	drio	Proceeds From Stock Options And Warrants Exercised ProceedsFromStockOptionsAndWarrantsExercised		USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	257000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
	drio	Proceeds From Issuance Of Common Stock And Warrants1 ProceedsFromIssuanceOfCommonStockAndWarrants1	0	USD
CY2015Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	261677	shares
CY2016Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	6.66
CY2016Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	300000	shares
CY2016Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.50
CY2016Q3	drio	Warrant Exercise Period WarrantExercisePeriod	P4Y6M
	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in" align="justify"></div> <table style="LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="72"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>NOTE 3:-</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><b><font style="FONT-SIZE: 10pt">UNAUDITED INTERIM FINANCIAL STATEMENTS</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0in 0in 0pt 85.05pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in" align="justify"><font style="FONT-SIZE: 10pt">The accompanying unaudited interim consolidated financial statements as of September 30, 2016, have been prepared in accordance with U.S. generally accepted accounting principles and standards of the Public Company Accounting Oversight Board for interim financial information. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements. In the opinion of management, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for a fair presentation of the Company's consolidated financial position as of September 30, 2016, and the Company's consolidated results of operations and the Company's consolidated cash flows for the nine months ended September 30, 2016. Results for the nine months ended September 30, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	259000	USD
CY2015Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	0	USD
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	650000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1564000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1439000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	650000	USD
	us-gaap	Revenue Recognition Software RevenueRecognitionSoftware	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"></div> <table style="LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">a.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Revenue recognition:</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in" align="justify"><font style="FONT-SIZE: 10pt">Revenues are recognized in accordance with Staff Accounting Bulletin ("SAB") No. 104, <i>Revenue Recognition</i>, when delivery has occurred or services have been rendered, persuasive evidence of an agreement exists, the seller's price to the buyer is fixed or determinable and collectability is probable.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -46.35pt; MARGIN: 0in 0in 0pt 56.7pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in" align="justify"><font style="FONT-SIZE: 10pt">The Company derives revenues from the sale of its Dario Smart Meter and its related device-specific disposables test strip cartridges and lancets through independent distributors or directly to end users. The Dario software application is offered for a free download and the Company does not obtain a recurring hosting commitment towards the end users relating specifically to the application.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in" align="justify"><font style="FONT-SIZE: 10pt">The Company generally has a standard contract with its distributors. According to the agreements, all sales to distributors are final, no right of return or price protection right is granted to such distributors and the Company is not a party to the agreements between distributors and their customers.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 56.7pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in" align="justify"><font style="FONT-SIZE: 10pt">Commencing July 1, 2016, product sales to distributors are recognized as revenues upon delivery as the fee is fixed or determinable and collectability is probable.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 56.7pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in" align="justify"><font style="FONT-SIZE: 10pt">The Company also generates revenues from arrangements with health care providers which include supply of Dario Smart Meters and software platform that requires certain customization followed by monthly service, support and maintenance.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 56.7pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in" align="justify"><font style="FONT-SIZE: 10pt">When a sales arrangement contains multiple elements, such as software and non-software components, the Company allocates revenue to each element based on a selling price hierarchy as required according to ASC 605-25, “Multiple-Element Arrangements”. The selling price for a deliverable is based on its Vendor Specific Objective Evidence (“VSOE”), if available, third party evidence (“TPE”) if VSOE is not available, or estimated selling price (“ESP”) if neither VSOE nor TPE is available. The best estimate of selling price is established considering several internal factors including, but not limited to, historical sales, pricing practices and geographies in which the Company offers its products. The determination of ESP is judgmental.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 56.7pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in" align="justify"><font style="FONT-SIZE: 10pt">Revenues from software components in sales arrangement contains multiple elements are recognized when all criteria outlined in ASC 985-605, “Software Revenue Recognition” (“ASC 985-605”), are met. Revenue from services is recognized when persuasive evidence of an arrangement exists, delivery of the product has occurred or the services have been rendered, the fee is fixed or determinable and collectability is probable.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 56.7pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in" align="justify"><font style="FONT-SIZE: 10pt">For multiple element arrangements within ASC 985-605, revenues are allocated to the different elements in the arrangement under the “residual method” when VSOE of fair value exist for all undelivered elements and no VSOE exists for the delivered elements. Under the residual method, at the outset of the arrangement with the customer, the fair value of the undelivered elements is deferred and the remaining portion of the arrangement fee is allocated to the delivered elements and is recognized as revenue when the basic criteria in ASC 985-605 have been met. Any discount in the arrangement is allocated to the delivered element.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 56.7pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in" align="justify"><font style="FONT-SIZE: 10pt">Since VSOE does not exist for undelivered elements, revenues are recognized as one unit of accounting, on a straight-line basis over the term of the last deliverable based on ASC 605-15, “Products” and ASC 985-605.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 56.7pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in" align="justify"><font style="FONT-SIZE: 10pt">Deferred revenues include advances and payments received from customers, for which revenue has not yet been recognized.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	650000	USD

Files In Submission

Name	View Source	Status
0001144204-16-133274-index-headers.html	Edgar Link	pending
0001144204-16-133274-index.html	Edgar Link	pending
0001144204-16-133274.txt	Edgar Link	pending
0001144204-16-133274-xbrl.zip	Edgar Link	pending
drio-20160930.xml	Edgar Link	completed
drio-20160930.xsd	Edgar Link	pending
drio-20160930_cal.xml	Edgar Link	unprocessable
drio-20160930_def.xml	Edgar Link	unprocessable
drio-20160930_lab.xml	Edgar Link	unprocessable
drio-20160930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v452113_10q.htm	Edgar Link	pending
v452113_ex31-1.htm	Edgar Link	pending
v452113_ex31-2.htm	Edgar Link	pending
v452113_ex32-1.htm	Edgar Link	pending
v452113_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DRIO
DarioHealth Corp. Stock $drio

2016 Q4 Form 10-Q Financial Statement

#000114420416133274 Filed on November 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DRIO DarioHealth Corp. Stock $drio

2016 Q4 Form 10-Q Financial Statement

#000114420416133274 Filed on November 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DRIO
DarioHealth Corp. Stock $drio